A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Public ClinicalTrials.gov record NCT04209855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
Study identification
- NCT ID
- NCT04209855
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 453 participants
Conditions and interventions
Interventions
- Mirvetuximab Soravtansine Drug
- Paclitaxel Drug
- Topotecan Drug
- Pegylated liposomal doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2019 (Actual)
- Primary completion
- Mar 6, 2023 (Actual)
- Completion
- Oct 29, 2024 (Actual)
- Last update posted
- Aug 27, 2025
2019 – 2024
United States locations
- U.S. sites
- 78
- U.S. states
- 34
- U.S. cities
- 69
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) GYN Oncology | Birmingham | Alabama | 35233 | — |
| Alaska Women's Cancer Care | Anchorage | Alaska | 99508 | — |
| Arizona Oncology Associates, PC - HAL - USOR | Phoenix | Arizona | 85016 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| USOR: Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85711 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit | Los Angeles | California | 90095 | — |
| Hoag Cancer Center | Newport Beach | California | 92663 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Olive View - UCLA Medical Center | Sylmar | California | 91324 | — |
| Kaiser Permanente Oncology Clinical Trials | Vallejo | California | 94589 | — |
| USOR: Rocky Mountain Cancer Centers | Lakewood | Colorado | 80228 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| Florida Cancer Specialist South Division | Fort Myers | Florida | 33901 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Sarasota Memorial Hospital | Sarasota | Florida | 34239 | — |
| Women's Care Florida / Women's Cancer Associates | St. Petersburg | Florida | 33701 | — |
| Florida Cancer Specialist North Division | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | Tallahassee | Florida | 32308 | — |
| Florida Cancer Specialist East Division | West Palm Beach | Florida | 33401 | — |
| Memorial University Medical Center | Savannah | Georgia | 31404 | — |
| Hawaii Pacific Health - Kapiolani Medical Center for Women and Children | Honolulu | Hawaii | 96813 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Dr. Sudarshan K. Sharma, Ltd. | Hinsdale | Illinois | 60521 | — |
| Community Health Network | Indianapolis | Indiana | 46250 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| St. Elizabeth Healthcare | Edgewood | Kentucky | 41017 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Ochnser Medical Center Jefferson | New Orleans | Louisiana | 70121 | — |
| WK Physicians Network/Gynecologic Oncology Associates | Shreveport | Louisiana | 771103 | — |
| Holy Cross Hospital | Silver Spring | Maryland | 20902 | — |
| USOR: Maryland Oncology Hematology, P.A. | Silver Spring | Maryland | 20902 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Baystate Medical Center | Springfield | Massachusetts | 01199 | — |
| University of Massachusetts | Worcester | Massachusetts | 01605 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| USOR: Minnesota Oncology Hematology, PA | Woodbury | Minnesota | 55125 | — |
| HCA Midwest Kansas City/ Sarah Cannon | Kansas City | Missouri | 64132 | — |
| Sletten Cancer Institute | Great Falls | Montana | 59405 | — |
| Center of Hope | Reno | Nevada | 89511 | — |
| The Valley Hospital, Inc | Ridgewood | New Jersey | 07450 | — |
| Holy Name Medical Center | Teaneck | New Jersey | 07666 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| FirstHealth of the Carolinas Outpatient Cancer Center | Pinehurst | North Carolina | 28374 | — |
| USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc. | Cincinnati | Ohio | 45242 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Columbus NCORP | Columbus | Ohio | 43215 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| Oncology_Hematology Care Clinical Trials, LLC | Fairfield | Ohio | 45014 | — |
| The Ohio State University Wexner Medical Center | Hilliard | Ohio | 43026 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oklahoma Cancer Specialists and Research Institute | Tulsa | Oklahoma | 74146 | — |
| USOR: Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Legacy Gynecologic Oncology | Portland | Oregon | 97210 | — |
| USOR: Northwest Cancer Specialists, P.C. | Portland | Oregon | 97227 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Magee-Women's Hospital-UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Women & Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Tennessee Oncology / Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| USOR: Texas Oncology-South Austin | Austin | Texas | 78745 | — |
| USOR: Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| University of Texas, Memorial Hermann | Houston | Texas | 77030 | — |
| USOR: Texas Oncology - McAllen South Second | McAllen | Texas | 78503 | — |
| USOR: Texas Oncology - San Antonio | San Antonio | Texas | 78240 | — |
| USOR: Texas Oncology, P.A. | Sugar Land | Texas | 77479 | — |
| USOR: Texas Oncology - The Woodlands, Gynecologic Oncology | The Woodlands | Texas | 77380 | — |
| USOR: Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| USOR: Texas Oncology, P.A. | Webster | Texas | 77598 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| USOR: Virginia Cancer Specialists, PC | Gainesville | Virginia | 20155 | — |
| Kadlec Clinic Hematology & Oncology | Kennewick | Washington | 99336 | — |
| West Virginia University- MBRCC | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04209855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04209855 live on ClinicalTrials.gov.